| 1. |
- Ferrario, M., et al.
(author)
-
IRIDE : Interdisciplinary research infrastructure based on dual electron linacs and lasers
- 2014
-
In: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 740, s. 138-146
-
Journal article (peer-reviewed)abstract
- This paper describes the scientific aims and potentials as well as the preliminary technical design of RUDE, an innovative tool for multi-disciplinary investigations in a wide field of scientific, technological and industrial applications. IRIDE will be a high intensity "particles factory", based on a combination of high duty cycle radio-frequency superconducting electron linacs and of high energy lasers. Conceived to provide unique research possibilities for particle physics, for condensed matter physics, chemistry and material science, for structural biology and industrial applications, IRIDE will open completely new research possibilities and advance our knowledge in many branches of science and technology. [RIDE is also supposed to be realized in subsequent stages of development depending on the assigned priorities.
|
|
| 2. |
|
|
| 3. |
- Smiljanic, R., et al.
(author)
-
The Gaia-ESO Survey: The analysis of high-resolution UVES spectra of FGK-type stars
- 2014
-
In: Astronomy & Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 570
-
Journal article (peer-reviewed)abstract
- Context. The ongoing Gaia-ESO Public Spectroscopic Survey is using FLAMES at the VLT to obtain high-quality medium-resolution Giraffe spectra for about 10(5) stars and high-resolution UVES spectra for about 5000 stars. With UVES, the Survey has already observed 1447 FGK-type stars. Aims. These UVES spectra are analyzed in parallel by several state-of-the-art methodologies. Our aim is to present how these analyses were implemented, to discuss their results, and to describe how a final recommended parameter scale is defined. We also discuss the precision (method-to-method dispersion) and accuracy (biases with respect to the reference values) of the final parameters. These results are part of the Gaia-ESO second internal release and will be part of its first public release of advanced data products. Methods. The final parameter scale is tied to the scale defined by the Gaia benchmark stars, a set of stars with fundamental atmospheric parameters. In addition, a set of open and globular clusters is used to evaluate the physical soundness of the results. Each of the implemented methodologies is judged against the benchmark stars to define weights in three different regions of the parameter space. The final recommended results are the weighted medians of those from the individual methods. Results. The recommended results successfully reproduce the atmospheric parameters of the benchmark stars and the expected T-eff-log g relation of the calibrating clusters. Atmospheric parameters and abundances have been determined for 1301 FGK-type stars observed with UVES. The median of the method-to-method dispersion of the atmospheric parameters is 55K for T-eff, 0.13dex for log g and 0.07 dex for [Fe/H]. Systematic biases are estimated to be between 50-100 K for T-eff, 0.10-0.25 dex for log g and 0.05-0.10 dex for [Fe/H]. Abundances for 24 elements were derived: C, N, O, Na, Mg, Al, Si, Ca, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Mo, Ba, Nd, and Eu. The typical method-to-method dispersion of the abundances varies between 0.10 and 0.20 dex. Conclusions. The Gaia-ESO sample of high-resolution spectra of FGK-type stars will be among the largest of its kind analyzed in a homogeneous way. The extensive list of elemental abundances derived in these stars will enable significant advances in the areas of stellar evolution and Milky Way formation and evolution.
|
|
| 4. |
- Ayas, Mouhab, et al.
(author)
-
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.
- 2013
-
In: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 31:13, s. 1669-76
-
Journal article (peer-reviewed)abstract
- PURPOSE Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed. PATIENTS AND METHODS We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007. Results Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (≤ v > 14 years: 69% [95% CI, 57% to 80%] v 39% [95% CI, 26% to 53%], respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (≤ v > 14 years: 78% [95% CI, 64% to 90%] v 34% [95% CI, 20% to 50%], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% [95% CI, 52% to 81%] v 43% [95% CI, 27% to 59%], respectively; P = .03) had superior 5-year survival. CONCLUSION Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival.
|
|
| 5. |
|
|
| 6. |
- Aplenc, Richard, et al.
(author)
-
Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.
- 2014
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 123:22, s. 3504-11
-
Journal article (peer-reviewed)abstract
- The rising incidence of pediatric obesity may significantly affect bone marrow transplantation (BMT) outcomes. We analyzed outcomes in 3687 children worldwide who received cyclophosphamide-based BMT regimens for leukemias between 1990 and 2007. Recipients were classified according to age-adjusted body mass index (BMI) percentiles as underweight (UW), at risk of UW (RUW), normal, overweight (OW), or obese (OB). Median age and race were similar in all groups. Sixty-one percent of OB children were from the United States/Canada. Three-year relapse-free and overall survival ranged from 48% to 52% (P = .54) and 55% to 58% (P = .81) across BMI groups. Three-year leukemia relapses were 33%, 33%, 29%, 25%, and 21% in the UW, RUW, normal, OW, and OB groups, respectively (P < .001). Corresponding cumulative incidences for transplant-related mortality (TRM) were 18%, 19%, 21%, 22%, and 28% (P < .01). Multivariate analysis demonstrated a decreased risk of relapse compared with normal BMI (relative risk [RR] = 0.73; P < .01) and a trend toward higher TRM (RR = 1.28; P = .014). BMI in children is not significantly associated with different survival after BMT for hematologic malignancies. Obese children experience less relapse posttransplant compared with children with normal BMI; however, this benefit is offset by excess in TRM.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Follert, R., et al.
(author)
-
CRIRES plus : a cross-dispersed high-resolution infrared spectrograph for the ESO VLT
- 2014
-
In: GROUND-BASED AND AIRBORNE INSTRUMENTATION FOR ASTRONOMY V. - : SPIE. - 9780819496157
-
Conference paper (peer-reviewed)abstract
- High-resolution infrared spectroscopy plays an important role in astrophysics from the search for exoplanets to cosmology. Yet, many existing infrared spectrographs are limited by a rather small simultaneous wavelength coverage. The AO assisted CRIRES instrument, installed at the ESO VLT on Paranal, is one of the few IR (0.92-5.2 mu m) high-resolution spectrographs in operation since 2006. However it has a limitation that hampers its efficient use: the wavelength range covered in a single exposure is limited to similar to 15 nanometers. The CRIRES Upgrade project (CRIRES+) will transform CRIRES into a cross-dispersed spectrograph and will also add new capabilities. By introducing cross-dispersion elements the simultaneously covered wavelength range will be increased by at least a factor of 10 with respect to the present configuration, while the operational wavelength range will be preserved. For advanced wavelength calibration, new custom made absorption gas cells and etalons will be added. A spectro-polarimetric unit will allow one for the first time to record circularly polarized spectra at the highest spectral resolution. This will be all supported by a new data reduction software which will allow the community to take full advantage of the new capabilities of CRIRES+.
|
|
| 10. |
- Oliva, E., et al.
(author)
-
Concept and optical design of the cross-disperser module for CRIRES
- 2014
-
In: GROUND-BASED AND AIRBORNE INSTRUMENTATION FOR ASTRONOMY V. - : SPIE. - 9780819496157
-
Conference paper (peer-reviewed)abstract
- CRIRES, the ESO high resolution infrared spectrometer, is a unique instrument which allows astronomers to access a parameter space which up to now was largely uncharted. In its current setup, it consists of a single-order spectrograph providing long-slit, single-order spectroscopy with resolving power up to R=100,000 over a quite narrow spectral range. This has resulted in sub-optimal efficiency and use of telescope time for all the scientific programs requiring broad spectral coverage of compact objects (e.g. chemical abundances of stars and intergalactic medium, search and characterization of extra-solar planets). To overcome these limitations, a consortium was set-up for upgrading CRIRES to a cross-dispersed spectrometer, called CRIRES+. This paper presents the updated optical design of the cross-dispersion module for CRIRES+. This new module can be mounted in place of the current pre-disperser unit. The new system yields a factor of >10 increase in simultaneous spectral coverage and maintains a quite long slit (10"), ideal for observations of extended sources and for precise sky-background subtraction.
|
|
| 11. |
- Saglio, Giuseppe, et al.
(author)
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
- 2010
-
In: The New England journal of medicine. - 1533-4406. ; 362:24, s. 2251-9
-
Journal article (peer-reviewed)abstract
- Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.
|
|
